Ezra E.W. Cohen, MD of University of California, San Diego gives an overview of presentations that were discussed at ASCO-SITC. He states that the conference focuses on the new and upcoming research and data in immuno-oncology, such as a new PDL-1, Avelumab. This was recorded at the ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando, Florida.
Avelumab in Merkel Cell Carcinoma Shows Extraordinary Response Rate
